Abstract
The Alzheimer' s disease (AD) diagnosis and therapy market is expanding with
increasing number of cases worldwide. The current scenario shows bright
outlook for diagnosis market. As early diagnosis of AD is not possible, there
is a strong need of an early detection technique. United States, Europe and
Japan are the three major markets for the treatment of AD. In China, the
diagnosis and drug treatment of Alzheimer' s disease is extremely low, which
represents a potential opportunity for market players.
The worldwide Alzheimer disease market is led by sales of Eisai/Pfizer and
Aricept. Eisai/Pfizer' s Aricept (donepezil) and Forest pharmaceutical' s
Namenda (memantine) are the market leaders in the United States. After
cardiovascular diseases and cancer, AD is the third largest market in the
world in terms of cost of treatment of the disease.
Aging population is a major cause of increasing number of Alzheimer patients
and driving AD diagnosis and treatment market. Urbanization also contributes
to the growing AD market. The unmet clinical needs are driving competitors to
focus on R&D which ultimately leads to new product introduction and helps in
market growth.
The present report analyzes Alzheimer' s disease treatment and diagnosis market
and discusses major drugs being used for the treatment of AD in United States,
Japan and China. It analyses major growth drivers and opportunities present in
the market. The report also discusses competition prevailing in the industry
and an overview of the leading companies and their business strategies. The
section on market forecast helps market players to develop business strategies
accordingly.
| 
View Cart
